.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB07_AlglucosidaseAlfa.AlglucosidaseAlfa .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB07_AlglucosidaseAlfa.AlglucosidaseAlfa| name: | AlglucosidaseAlfa | |
| ATC code: | A16AB07 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 20 | mg |
| volume of distribution: | 84.1 | L |
| clearance: | 19.9 | mL/h/kg |
| other parameters in model implementation | ||
Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme replacement therapy approved for the treatment of Pompe disease (glycogen storage disease type II), a rare genetic disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase. It is administered to help reduce glycogen accumulation in tissues, primarily skeletal and cardiac muscle.
Pharmacokinetics in patients with Pompe disease, both infantile-onset and late-onset, after intravenous infusion. Estimates from published clinical studies in both pediatric and adult populations.